Dose-escalated Simultaneous Integrated-boost Treatment of Prostate Cancer Patients Via Helical Tomotherapy

Overview

Journal Strahlenther Onkol

Specialties Oncology
Radiology

Date 2012 Feb 28

PMID 22367410

Citations 18

Authors

M Geier

S T Astner

M N Duma

V Jacob

C Nieder

J Putzhammer

C Winkler

M Molls

H Geinitz

Affiliations

Soon will be listed here.

Abstract

Purpose: The goal of this work was to assess the feasibility of moderately hypofractionated simultaneous integrated-boost intensity-modulated radiotherapy (SIB-IMRT) with helical tomotherapy in patients with localized prostate cancer regarding acute side effects and dose-volume histogram data (DVH data).

Methods: Acute side effects and DVH data were evaluated of the first 40 intermediate risk prostate cancer patients treated with a definitive daily image-guided SIB-IMRT protocol via helical tomotherapy in our department. The planning target volume including the prostate and the base of the seminal vesicles with safety margins was treated with 70 Gy in 35 fractions. The boost volume containing the prostate and 3 mm safety margins (5 mm craniocaudal) was treated as SIB to a total dose of 76 Gy (2.17 Gy per fraction). Planning constraints for the anterior rectal wall were set in order not to exceed the dose of 76 Gy prescribed to the boost volume. Acute toxicity was evaluated prospectively using a modified CTCAE (Common Terminology Criteria for Adverse Events) score.

Results: SIB-IMRT allowed good rectal sparing, although the full boost dose was permitted to the anterior rectal wall. Median rectum dose was 38 Gy in all patients and the median volumes receiving at least 65 Gy (V65), 70 Gy (V70), and 75 Gy (V75) were 13.5%, 9%, and 3%, respectively. No grade 4 toxicity was observed. Acute grade 3 toxicity was observed in 20% of patients involving nocturia only. Grade 2 acute intestinal and urological side effects occurred in 25% and 57.5%, respectively. No correlation was found between acute toxicity and the DVH data.

Conclusion: This institutional SIB-IMRT protocol using daily image guidance as a precondition for smaller safety margins allows dose escalation to the prostate without increasing acute toxicity.

Citing Articles

Dosimetric feasibility of moderately hypofractionated/dose escalated radiation therapy for localised prostate cancer with intensity-modulated proton beam therapy using simultaneous integrated boost (SIB-IMPT) and impact of hydrogel prostate-rectum....

Ahmad Khalil D, Jazmati D, Geismar D, Wulff J, Baumer C, Kramer P Radiat Oncol. 2022; 17(1):64.

PMID: 35365170 PMC: 8973648. DOI: 10.1186/s13014-022-02025-2.

Definitive, intensity modulated tomotherapy with a simultaneous integrated boost for prostate cancer patients - Long term data on toxicity and biochemical control.

Schiller K, Geier M, Duma M, Nieder C, Molls M, Combs S Rep Pract Oncol Radiother. 2019; 24(4):315-321.

PMID: 31193851 PMC: 6543185. DOI: 10.1016/j.rpor.2019.05.004.

Intraoperative Period and Breast Cancer: Review.

Akan A, Simsek S J Breast Health. 2017; 10(4):190-196.

PMID: 28331670 PMC: 5351514. DOI: 10.5152/tjbh.2014.2117.

Design and implementation of a "cheese" phantom-based Tomotherapy TLD dose intercomparison.

Schiefer H, Buchauer K, Heinze S, Henke G, Plasswilm L Strahlenther Onkol. 2015; 191(11):855-61.

PMID: 26087907 DOI: 10.1007/s00066-015-0850-2.

Moderate hypofractionation and simultaneous integrated boost by helical tomotherapy in prostate cancer: monoinstitutional report of acute tolerability assessment with different toxicity scales.

Ferrera G, Mortellaro G, Mannino M, Caminiti G, Spera A, Figlia V Radiol Med. 2015; 120(12):1170-6.

PMID: 26002724 DOI: 10.1007/s11547-015-0555-8.

References

Kotte A, Hofman P, Lagendijk J, van Vulpen M, van der Heide U . Intrafraction motion of the prostate during external-beam radiation therapy: analysis of 427 patients with implanted fiducial markers. Int J Radiat Oncol Biol Phys. 2007; 69(2):419-25. DOI: 10.1016/j.ijrobp.2007.03.029. View

Guckenberger M, Ok S, Polat B, Sweeney R, Flentje M . Toxicity after intensity-modulated, image-guided radiotherapy for prostate cancer. Strahlenther Onkol. 2010; 186(10):535-43. DOI: 10.1007/s00066-010-2144-z. View

Roach 3rd M, Hanks G, Thames Jr H, Schellhammer P, Shipley W, Sokol G . Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65(4):965-74. DOI: 10.1016/j.ijrobp.2006.04.029. View

Peeters S, Heemsbergen W, Koper P, van Putten W, Slot A, Dielwart M . Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006; 24(13):1990-6. DOI: 10.1200/JCO.2005.05.2530. View

Geinitz H, Thamm R, Keller M, Astner S, Heinrich C, Scholz C . Longitudinal study of intestinal symptoms and fecal continence in patients with conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010; 79(5):1373-80. DOI: 10.1016/j.ijrobp.2010.01.033. View

Fiorino C, Di Muzio N, Broggi S, Cozzarini C, Maggiulli E, Alongi F . Evidence of limited motion of the prostate by carefully emptying the rectum as assessed by daily MVCT image guidance with helical tomotherapy. Int J Radiat Oncol Biol Phys. 2008; 71(2):611-7. DOI: 10.1016/j.ijrobp.2008.01.048. View

Proust-Lima C, Taylor J, Secher S, Sandler H, Kestin L, Pickles T . Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics. Int J Radiat Oncol Biol Phys. 2010; 79(1):195-201. PMC: 4122313. DOI: 10.1016/j.ijrobp.2009.10.008. View

Guckenberger M, Flentje M . Intensity-modulated radiotherapy (IMRT) of localized prostate cancer: a review and future perspectives. Strahlenther Onkol. 2007; 183(2):57-62. DOI: 10.1007/s00066-007-1631-3. View

Singh A, Guion P, Sears-Crouse N, Ullman K, Smith S, Albert P . Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study. Radiat Oncol. 2007; 2:36. PMC: 2075521. DOI: 10.1186/1748-717X-2-36. View

10.

Zietman A, Bae K, Slater J, Shipley W, Efstathiou J, Coen J . Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol. 2010; 28(7):1106-11. PMC: 2834463. DOI: 10.1200/JCO.2009.25.8475. View

11.

Kupelian P, Willoughby T, Reddy C, Klein E, Mahadevan A . Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys. 2007; 68(5):1424-30. DOI: 10.1016/j.ijrobp.2007.01.067. View

12.

Dearnaley D, Sydes M, Graham J, Aird E, Bottomley D, Cowan R . Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007; 8(6):475-87. DOI: 10.1016/S1470-2045(07)70143-2. View

13.

Nickers P, Hermesse J, Deneufbourg J, Vanbelle S, Lartigau E . Which α/β ratio and half-time of repair are useful for predicting outcomes in prostate cancer?. Radiother Oncol. 2010; 97(3):462-6. DOI: 10.1016/j.radonc.2010.06.006. View

14.

Dolezel M, Odrazka K, Vaculikova M, Vanasek J, Sefrova J, Paluska P . Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy. Strahlenther Onkol. 2010; 186(4):197-202. DOI: 10.1007/s00066-010-2065-x. View

15.

Keiler L, Dobbins D, Kulasekere R, Einstein D . Tomotherapy for prostate adenocarcinoma: a report on acute toxicity. Radiother Oncol. 2007; 84(2):171-6. DOI: 10.1016/j.radonc.2007.07.012. View

16.

Kassim I, Dirkx M, Heijmen B . Evaluation of the dosimetric impact of non-exclusion of the rectum from the boost PTV in IMRT treatment plans for prostate cancer patients. Radiother Oncol. 2009; 92(1):62-7. DOI: 10.1016/j.radonc.2009.02.004. View

17.

Junius S, Haustermans K, Bussels B, Oyen R, Vanstraelen B, Depuydt T . Hypofractionated intensity modulated irradiation for localized prostate cancer, results from a phase I/II feasibility study. Radiat Oncol. 2007; 2:29. PMC: 1971267. DOI: 10.1186/1748-717X-2-29. View

18.

Brenner D . Hypofractionation for prostate cancer radiotherapy--what are the issues?. Int J Radiat Oncol Biol Phys. 2003; 57(4):912-4. DOI: 10.1016/s0360-3016(03)01456-1. View

19.

Li X, Wang J, Jursinic P, Lawton C, Wang D . Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2005; 61(4):1251-7. DOI: 10.1016/j.ijrobp.2004.11.034. View

20.

Zelefsky M, Chan H, Hunt M, Yamada Y, Shippy A, Amols H . Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006; 176(4 Pt 1):1415-9. DOI: 10.1016/j.juro.2006.06.002. View